Skip to content

A STUDY TO COMPARE THE EFFECTIVENESS AND SAFETY OF INTRALESIONAL VITAMIN D3 WITH INTRALESIONAL TRIAMCINOLONE IN PATIENTS WITH KELOIDS.

A DOUBLE-BLINDED RANDOMIZED CONTROL STUDY TO COMPARE THEEFFECTIVENESS AND SAFETY OF INTRALESIONAL VITAMIN D3 WITH INTRALESIONAL TRIAMCINOLONE AND ITâ??S CORRELATION WITH TISSUE EXPRESSION OF VITAMIN D RECEPTORS IN PATIENTS WITH KELOID

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039579
Enrollment
58
Registered
2022-01-19
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L910- Hypertrophic scar

Interventions

Intervention1: INJECTION VITAMIN D3: DOSE- Intralesional injection of vitamin D3 at 0.2 ml(200,000 IU)with a dose of 0.2 ml per cm2of keloid. Frequency- Once every 4 weekly for 4 months. Route - Intra

Sponsors

DEPARTMENT OF DERMATOLOGY PGIMER CHANDIGARH
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient with single keloid or multiple (upper limit 5) of more than 6-month duration. Every keloid selected for study is considered a different entity. 2. Keloids of size 3. The patient who can give valid consent.

Exclusion criteria

Exclusion criteria: 1. Patient with any previous interventional treatment for the same keloid in the 6 months preceding enrollment 2. Pregnant or lactating females or women who are planning a pregnancy 3. Keloids on the face 4. Immunosuppressed patients 5. Patient with chronic inflammatory diseases; patients with a history of renal or liver failure 6.Patients with a history of hypersensitivity to any of the study drugs 7. Patients with a history of non-responsiveness to any of the treatment modalities 8. The patient who is not willing to provide consent for the study. 9. Patient with active inflammation, infection, or ulcer in and around the keloid

Design outcomes

Primary

MeasureTime frame
Proportion of patient achieving 50% reduction in scar score by measuring the difference in Vancouver scar scale in the group receiving intralesional injection vitamin D3 versus the injection triamcinolone group.Timepoint: At the end of 4,8,12,16,24 weeks

Secondary

MeasureTime frame
Adverse events during the treatmentTimepoint: At the end of 4,8,12,16,24 weeks;Mean difference in quality of life of patients before and after treatmentTimepoint: At the end of 4,8,12,16,24 weeks;To determine differences in VDR expression in keloid pathology by comparing tissue VDR expression pre and post-treatmentTimepoint: At the end of 4,8,12,16,24 weeks

Countries

India

Contacts

Public ContactDr Aman goyal

PGIMER CHANDIGARH

narangtarun2012@gmail.com9316063166

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026